U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

ARTEFENOMEL

MORE DETAILS

  RIK029813G

Status:
Investigational
Source:
NCT02083380: Phase 2/Phase 3 Interventional Completed Uncomplicated Plasmodium Falciparum Malaria
(2014)
Source URL:
https://clinicaltrials.gov/ct2/show/NCT02083380
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
gametophyte development
2
Conditions:
Plasmodium falciparum malaria
63
Artefenomel, a novel trioxolane, is a lead candidate for inclusion in a new antimalarial combination, specifically formulated for children. Artefenomel has been demonstrated curative in as little as one dose.

ARTEFENOMEL MESYLATE

MORE DETAILS

  PXW0Q9H3IJ

Status:
Investigational
Source:
NCT02083380: Phase 2/Phase 3 Interventional Completed Uncomplicated Plasmodium Falciparum Malaria
(2014)
Source URL:
https://clinicaltrials.gov/ct2/show/NCT02083380
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
gametophyte development
2
Conditions:
Plasmodium falciparum malaria
63
Artefenomel, a novel trioxolane, is a lead candidate for inclusion in a new antimalarial combination, specifically formulated for children. Artefenomel has been demonstrated curative in as little as one dose.
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966